Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks, given with comprehensive standard of care (hospitalization ≥5 days and newly initiated or optimized oral antidepressant[s]). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale total score (primary efficacy endpoint) was analyzed using ANCOVA. Clinical Global Impression–Severity of Suicidality–revised (key secondary endpoint) was analyzed using ANCOVA on ranks of change. Results: Of 230 patients who were randomized (115 per arm), 227 received study drug and were included in efficacy/safety analyses; 184 (80.0%) completed double-blind treatment. Greater improvement in Montgomery-Asberg Depression Rating Scale total score was observed with esketamine (mean [SD]: –15.7 [11.56]) vs placebo (–12.4 [10.43]), each with standard of care, at 24 hours (least-squares mean difference [SE]: –3.9 [1.39], 95% CI: –6.60, –1.11; 2-sided P = .006). This was also noted at the earlier (4-hour) timepoint (least-squares mean difference –4.2, 95% CI: –6.38, –1.94). Patients in both treatment groups experienced rapid reduction in Clinical Global Impression–Severity of Suicidality–revised score; the between-group difference was not statistically significant. The most common adverse events among esketamine-treated patients were dizziness, dissociation, nausea, dysgeusia, somnolence, headache, and paresthesia. Conclusion: This study confirmed rapid and robust reduction of depressive symptoms with esketamine nasal spray in severely ill patients with MDD who have active suicidal ideation with intent. Trial Registration: Clinical Trials.gov identifier: NCT03097133
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least-square mean changes (±SE) from baseline for Montgomery-Asberg Depression Rating Scale (MADRS) total score during the double-blind treatment phase (mixed-effects model using repeated measures [MMRM]; observed cases). aIncludes patients who had their dose reduced due to tolerability issues. Note: Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/867338dabcaf42aca05b1ca83661094a/esketamine-nasal-spray-for-rapid-reduction-of-depressive-symptoms-in-patients-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“a nasal spray form of S-ketamine was approved by the Food and Drug Administration (FDA) in the USA and by the European Medicines Agency (EMA) in Europe in 2019 [18].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Risk factors for suicide in psychiatric outpatients: A 20-year prospective study.
Brown, G. K., Beck, A. T., Steer, R. A., & Grisham, J. R. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.3.371 · Cited by 1,317 · cited 1×
“Nearly all patients with MDD who attempt or complete suicide have suicidal ideation prior to the event (Brown et al., 2000; Sokero et al., 2003).”
BackgroundValidity and Reliability of the Observer??s: Assessment of Alertness/Sedation Scale
CHERNIK, D. A., GILLINGS, D., LAINE, H., HENDLER, J., SILVER, J. M., DAVIDSON, A. B., SCHWAM, E. M., & SIEGEL, J. L. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199008000-00003 · Cited by 1,246
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Self-citationWilliams, J. B. W., & Kobak, K. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.032532 · Cited by 463 · cited 1×
“Eligible patients were between 18 and 64 years of age, met the Diagnostic and Statistical Manual of Mental Disorders–5th edition (DSM-5) criteria (American Psychiatric Association, 2013) for MDD (without psychosis) based on diagnostic assessment with the Mini International Neuropsychiatric Interview, and had a MADRS (…”
MethodPractice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.56008 · Cited by 406
The European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390 · cited 3×
“Current standard of care includes initiation or optimization of oral antidepressants and, frequently, hospitalization (American Psychiatric Association, 2003; Wasserman et al., 2012).”
Background
Research works printed but not linked: 1
- Spravato (esketamine) nasal spray. Prescribing information. 2020. Janssen Pharmaceutical Companies.
Cited by
Items 401–418 of 418
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_16
Martínez‐Gras, I., Molina, J. D. D., Sánchez-Pastor, L., Llamas, S., Espejo-Saavedra, J. M., Compaired, A., Leza, J. C., & Rubio, G. (2026) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2026.100332
Vom Notfallmedikament zum Therapiebaustein? Ketamin im Umgang mit Suizidalität
Volkmann, C., Aldinger, L.-M., & Köhler, S. (2026) · PiD - Psychotherapie im Dialog · doi:10.1055/a-2643-2282
“Volkmann Placebo in Bezug auf sui zidale Gedanken [3], selbst in den qualitativ hochwerti gen Zulassungsstudien, die speziell hierfür durchgeführt wurden [4].”
Qu, Y., Li, S., Tian, L., Tian, X., & Wu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1792570 · Cited by 1
A pilot randomized trial of ketamine for suicidal ideation in a pediatric emergency department
Onikashvili, Y., Burt, H., Meckler, G. D., Bone, J. N., Hind, T., Sih, K., Sassi, R., Stillwell, K., Black, T. R., & Doan, Q. H. (2026) · Canadian Journal of Emergency Medicine · doi:10.1007/s43678-026-01190-7
“[9, 27, 29] Given the gender diverse study population, we recommend collecting preferred names and pronouns, which has been shown to improve survey satisfaction among gender diverse individuals [36].”
Benster, L. L., Kohn, J. N., Wade, B., Stapper, N., Weissman, C. R., Miron, J., Daskalakis, Z. J., & Appelbaum, L. G. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122107 · Cited by 2
“As SI outcomes in past pivotal trials did not clearly separate from placebo (Fu et al., 2020)(Ionescu et al., 2021), nonspecific factors (e.g., intensive monitoring/clinical contact) may contribute, especially given the longer in-clinic time for esketamine (~2 h) versus rTMS (minutes).”
Lv, Y., Yang, Z., Li, L., Xu, Y., Qin, Y., Deng, B., & ZHAI, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179153 · Cited by 1
Wu, Q., Li, W., Luo, Z., Wang, C., Lan, X., Shen, J., Chen, Z. X., Pan, J., Liu, X., Zhu, H., et al. (2026) · BMC Psychiatry · doi:10.21203/rs.3.rs-10020524/v1
Gu, T., Zhang, J., Wang, R., Guo, F., Shu, W., Ouyang, Q., He, R., Zhang, T., Zheng, Q., Sun, L., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122307
The functional role of ERK activity in esketamine's antidepressant effects
Zhang, P. X., Wu, M., Zhang, K., He, J., Liu, X., Zhang, H., Hu, A. Z., & Zhou, W. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174248
Pinzi, M., Cuomo, A., Rescalli, M. B., Pierini, C., & Fagiolini, A. M. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2714839
“The strongest randomized evidence in adults with MDD and acute suicidal ideation or behavior comes from the phase III ASPIRE I and ASPIRE II trials [24,25].”
InfluentialLouka, P., Pitsillides, A. A., Koumas, M., Papacharalambous, C., Sophocleous, A., & Zanos, P. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag044
“72 , 73 By contrast, the arketamine enantiomer has shown favorable behavioural and tolerability profiles in preclinical studies, 74 but clinical evidence remains limited: An early open-label pilot study reported encouraging antidepressant signals, whereas adequately powered controlled trials are…”
Oncology Providers’ Perspectives on Psychedelic-Assisted Therapy
Hanubal, K. S., Munjal, A., Park, J., Banks, R., Choi, E., Hoyt, M. A., Humphreys, J., Mojtahedzadeh, M., & Harris, J. P. (2026) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091261483604
Wang, Y., Storaci, A. S., Alexander, G. C., & Gibbons, J. B. (2026) · Drug Safety · doi:10.1007/s40264-026-01722-1
Treatments for individuals with suicidal thoughts: Use, indications, and helpfulness
Ballard, E. D., Hafermann, H. F., Hurst, K. T., Farmer, C., Greenstein, D. K., Kvarta, M. D., May, A. M., & Zarate, C. A. (2026) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2026.101165
Xiao, W., Zhang, H., Chen, X., Cai, J., 駱旭琛, & Deng, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1956736
“The standards also speci fi ed the warning signs that required explicit recognition and the minimum safety-netting needed to support continued monitoring outside urgent care (45).”
Borkowska, M., Witaszczyk, M., Sołtan, A., Wiktorzak, N., Lipska, J., Prządka, J., Kochan-Olszewska, D., Rudnicki, L., Pawlicki, J., Laskus, J., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6636
“(3,4,15,16) A key randomized, midazolam-controlled trial included 80 adults with major depressive disorder and clinically significant suicidal ideation.”
Kinney, M. M., & Bowers, Z. L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1949261
“In contrast to conventional antidepressants that target dopamine, norepinephrine, or serotonin systems, esketamine antagonizes the NMDA receptors, increasing synaptic plasticity, thereby culminating in rapidly improved mood levels and increased cognitive abilities (19, 60).”
Metadata
- Authors
- Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M.
- Affiliations
- Department of Neuroscience, Janssen Research and Development, LLC, San Diego, CA
- Janssen Research & Development (United States) (US)
- Medical University of Vienna (AT)
- Corresponding author
- Ionescu, Dawn F
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-29
- Volume
- 24
- Issue
- 1
- Pages
- 22-31
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7816667
- OpenAlex
- W3082490768
- Cited by
- 418
- References
- 28
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 41 · 2023: 49 · 2022: 43 · 2021: 31 · 2020: 161
- FWCI
- 42.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- esketamine, nasal spray, major depressive disorder, rapid-acting antidepressants, depressive symptoms, suicidality, hospitalization, adverse events, dissociation
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Outcome Assessment, Health Care, Young Adult, Suicidal Ideation, Nasal Sprays, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.